was conducted from 2006 -2014 comparing the observed impact of PCVs on incidence of disease compared to the pre-PCV level of disease to estimate the cumulative impact of vaccination. Epidemiological databases were revised for incidence of invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM). Vaccination and direct clinical costs were obtained from public tabulators from 2018. Given the retrospective analysis, a prospective cost-benefit analysis was calculated based on continued use of PCV13. Results: When considering the hypothetical scenario of non-immunization vs immunization the use of PCVs in Mexico is estimated to have prevented approximately 1.5 million cases of pneumococcal disease and 1,840 deaths over the past 10 years. This reduction corresponds to over a $33 billion MXN costsavings since the introduction of PCVs. Prospectively, over a one year period continued PCV13 in Mexico provides a return on investment of $2.1 MXN for each peso invested in the program. ConClusions: PCVs in Mexico have resulted in a significant impact on PD incidence and a net economic benefit. PCVs in the current schedule should be maintained in order to maximize the total benefits of vaccination.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.